Novocure Q3 revenue beats estimates

NovoCure

30/10/2025 11:16

Overview

Novocure Q3 revenue rises 8% yr/yr, beating analyst expectations

Company submitted FDA application for TTFields therapy in pancreatic cancer

Net loss for Q3 was $37.3 mln, with decreased gross margin

Outlook

Novocure expects to have four indications in market by year-end 2026

Company plans to submit PMA application for brain metastases from NSCLC in Q4 2025

Topline data from Phase 2 PANOVA-4 trial in metastatic pancreatic cancer expected in Q1 2026

Result Drivers

ACTIVE PATIENT GROWTH - Revenue increase driven by growth in active patients and $3.3 mln exchange rate benefits

GEOGRAPHIC EXPANSION - Steady commercial execution in glioblastoma and geographic expansion contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$167.20 mln
$158.60 mln (7 Analysts)
Q3 Net Income
-$37.27 mln
Q3 Gross Profit
$122.47 mln
Q3 Operating Income
-$36.02 mln
Q3 Pretax Profit
-$30.02 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Novocure Ltd is $27.50, about 51% above its October 29 closing price of $13.48

Press Release: ID:nBw26NfKZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)